Emtriva (emtricitabine) NDC 61958-0601

NDC codes

FDA NDC Directory

Product NDC (as listed)61958-0601Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61958-0601Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61958-0601-1	61958060101	30 CAPSULE in 1 BOTTLE, PLASTIC (61958-0601-1)Marketed from Jul 2, 2003

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Emtriva
Generic name (nonproprietary): emtricitabine
Active ingredients: Emtricitabine — 200 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Gilead Sciences, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021500
Marketing start: Jul 2, 2003
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleosides (Chemical structure)
Identifiers: Product ID 61958-0601_13ed3577-67a4-4828-b886-f35206f149a6SPL ID 13ed3577-67a4-4828-b886-f35206f149a6SPL set ID d6599395-3944-44f9-97f2-e0424c6b6a1fRxCUI 403875, 404587, 597291, 616148UNII G70B4ETF4S
Pharmacologic class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N461958060101 followed by a unit qualifier and the quantity

Package 61958-0601-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 2, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

EMTRIVA ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. EMTRIVA, a nucleoside analog HIV-1 reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)